Mild Cognitive Impairment

Emory Alzheimer's Disease Research Center Honor Research Registry

James Lah, MD, PhD
Clinical Core Leader, Emory Alzheimer's Disease Research Center

Felicia Goldstein, PhD
Clinical Core Co-Leader, Emory Alzheimer's Disease Research Center

The purpose of Honor is to have a group of volunteers who want to participate in future research studies on memory & thinking.    By joining Honor you will learn about new research studies that are seeking volunteers.  You will also receive our newsletter and invitations to educational events. 

All Honor volunteers must have a “study partner” accompany them to their research visit.  Your study partner will be asked questions about your memory and thinking.  They will also be asked about your day to day functioning.  A study partner is someone who has at least 10 hours of contact with you each week.

For more information about this research study, please call Erin Carter at 404-712-6838 or email erin.carter@emory.edu.


ADNI-3

Allan Levey, MD, PhD
Director, Emory Alzheimer's Disease Research Center
Emory University Department of Neurology

Long-term study (2-4 years) being conducted as part of the Alzheimer’s Disease Neuroimaging Initiative to characterize changes in the brain associated with MCI and AD. Subjects will under multiple MRI and PET scans, lumbar puncture, blood draws and cognitive testing. 

For more information about this research study, please call Becky Byram at 404-712-0195 or email rbyram@emory.edu.


EXERT

Whitney Wharton, PhD
Emory University Department of Neurology

Joe Nocera, PhD

18-month study to examine the effects of aerobic exercise on cognition. Subjects with a diagnosis of mild cognitive impairment or a subjective memory complaint will be randomly assigned to undergo aerobic exercise or stretching/balance/rang-of-motion training for 4 dyas/week for 12 months at a local YMCA. Participants will be asked to agree to an MRI scan and an optional lumbar puncture, as well as cognitive assessments, blood draws, and a 400-meter walking test.

For more information about this research study, please call Morgan Hecker at 404-712-4463 or email morgan.hecker@emory.edu.


BAN2401-301: Clarity

Allan Levey, MD, PhD

This multinational study is using a placebo or the study drug, to determine safety and efficacy and to explore the dose response of this drug. In this 18-month study, a drug/placebo is infused biweekly (once every 2 weeks). Subjects will be from 2 clinical subgroups: MCI due to Alzheimer's disease (AD) or mild Alzheimer's disease dementia. Effectiveness of drug treatment will be assessed using cognitive tests, as well as biological markers (MRI, PET, CSF, blood).

For more information about this research study, please call Michelle Wiles at 404-778-0664 or email mkwiles@emory.edu.

Link to study website ยป


GRADUATE

Ihab Hajjar, MD

The study will consist of a screening period of up to 12 weeks in length following the signing of informed consent. Eligible patients will then undergo baseline visit assessments (Day 1) prior to receiving the first dose of blinded study drug (gantenerumab or placebo). Patients will continue in the double-blind treatment period for 104 weeks.

For more information about this research study, please call Deborah Westover at 404-712-6807 or email dwestov@emory.edu.


EMERALD

Ihab Hajjar, MD

This is a one-year, double-blind placebo-controlled randomized clinical trial that compares montelukast to placebo in individuals with mild cognitive impairment (MCI) and early Alzheimer's disease (AD) dementia. The measures include cognitive function, CSF biomarkers and neuroimaging (cerebral perfusion and markers of vascular brain damage).

Participants will be treated with montelukast (escalating doses:10, 20 to 40 mg) or matched placebo.

For more information about this research study, please call Shakyra Tyus at 404-712-6332 or email shakyra.d.tyus@emory.edu.